Progress in Cardiovascular Diseases
Volume 46, Issue 1 , Pages 39-78, July 2003

The economics of smoking and cardiovascular disease

  • James Lightwood

      Affiliations

    • Corresponding Author InformationReprint requests: James Lightwood, PhD, School of Pharmacy, Department of Clinical Pharmacy, University of California, San Francisco, 3333 California St, Suite 420, San Francisco, CA 94118, USA
    • School of Pharmacy, Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA, USA

Abstract 

The direct medical cost of cardiovascular and circulatory diseases was $151 billion in 1995, approximately 17% of all direct medical care costs in the United States. Incidence and prevalence based estimates indicate that smoking is a major contributing factor for cardiovascular disease and associated costs. Statewide smoking control programs and workplace and public area smoking bans are effective in reducing smoking prevalence. Smoking cessation therapies are very cost-effective interventions for the prevention of cardiovascular disease. Incidence based estimates indicate that smoking cessation control expenditures in the United States have been a cost effective method for reducing the direct medical costs of cardiovascular disease in the past, and may be cost saving in the future. The expected cost of producing an additional ex-smoker has been estimated to be approximately $1,000 to $1,500. Most or all of this cost can be recovered in the short run from savings in avoided heart attacks and strokes alone in healthy quitters. Observational studies of the direct medical costs following cessation in those observed to quit show a reduction utilization, but which may occur only after a lag of three to five years.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by the Flight Attendant Medical Research Institute and the California Tobacco-Related Disease Research Program (California TRDRP) grant 8RT-0007.

PII: S0033-0620(03)00077-X

doi:10.1016/S0033-0620(03)00077-X

Progress in Cardiovascular Diseases
Volume 46, Issue 1 , Pages 39-78, July 2003